Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PGNX
Previous Symbol
CUSIP74318710
Phone646-975-2500
Debt
Debt-to-Equity Ratio0.33
Current Ratio9.51
Quick Ratio9.51
Price-To-Earnings
Trailing P/E Ratio-5.07
Forward P/E Ratio-6.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.70 million
Price / Sales32.95
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.90 per share
Price / Book5.07
Profitability
EPS (Most Recent Fiscal Year)($0.90)
Net Income$-51,010,000.00
Net Margins-341.78%
Return on Equity-66.86%
Return on Assets-33.00%
Miscellaneous
Employees64
Outstanding Shares84,540,000
Market Cap$385.52 million
OptionableOptionable
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.09. The biotechnology company earned $5.32 million during the quarter, compared to analysts' expectations of $4.14 million. Progenics Pharmaceuticals had a negative return on equity of 66.86% and a negative net margin of 341.78%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
4 brokers have issued 12 month price targets for Progenics Pharmaceuticals' stock. Their predictions range from $6.50 to $15.00. On average, they anticipate Progenics Pharmaceuticals' share price to reach $11.6250 in the next year. This suggests a possible upside of 154.9% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.
What is the consensus analysts' recommendation for Progenics Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.
What are Wall Street analysts saying about Progenics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (11/10/2018)
- 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development." (5/20/2018)
Has Progenics Pharmaceuticals been receiving favorable news coverage?
News articles about PGNX stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Cambrex (CBM), Corcept Therapeutics (CORT), Theravance Biopharma (TBPH), Vanda Pharmaceuticals (VNDA), Enanta Pharmaceuticals (ENTA), Wave Life Sciences (WVE), Esperion Therapeutics (ESPR), Portola Pharmaceuticals (PTLA), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Mirati Therapeutics (MRTX), Tricida (TCDA) and Myovant Sciences (MYOV).
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 63)
- Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 50)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 61)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 45)
- Melissa Downs, Sr. Mang. of Investor Relations
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.72%), Vanguard Group Inc. (5.97%), Eagle Asset Management Inc. (5.26%), Phocas Financial Corp. (2.05%), Pinnacle Associates Ltd. (1.81%) and Royce & Associates LP (1.72%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which major investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Pinnacle Associates Ltd., FMR LLC, TIAA CREF Investment Management LLC, Hikari Power Ltd, Rice Hall James & Associates LLC, Virtus ETF Advisers LLC and Fisher Asset Management LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which major investors are buying Progenics Pharmaceuticals stock?
PGNX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Fosun International Ltd, Royce & Associates LP, Bank of New York Mellon Corp, Virtu Financial LLC, Creative Planning and Alps Advisors Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $4.56.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $385.52 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.
What is Progenics Pharmaceuticals' official website?
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
